She doesn't design the molecules. She makes sure the molecules find their money - across two hemispheres, in two languages of finance.
Kimberly Nearing, MA - the handshake at the center of the deal.
At MaveriX Oncology, a Palo Alto outfit trying to wake up the cancers that immunotherapy sleeps through, the science is a mouthful: tumor-selective small molecule drug conjugates, hydroxylase-releasable masking, conditional activation inside the tumor microenvironment. Kimberly Nearing's title is Chief Business Officer, which is a polite way of saying she is the person who makes sure all of that has a runway.
A three-person company with a Series A behind it and a platform aimed at "cold" tumors lives or dies on two things: whether the chemistry works, and whether the right investors believe it will. Nearing owns the second one. Business development, corporate strategy, commercialization, investor relations - the unglamorous machinery that turns a promising compound into a funded program. She has been doing exactly this, in one form or another, for more than twenty years.
What makes her unusual is not the title. Plenty of biotechs have a CBO. What makes her unusual is the map she carries in her head: a working atlas of where life sciences capital actually pools, and how to move a deal from a lab bench in California to a fund in Shanghai without anything getting lost in translation.
The U.S. - Greater China life sciences corridor: where Nearing has spent the better part of two decades.
For over a decade, Nearing was Managing Director and Head of Life Sciences at the Cedrus Group, a Hong Kong-based boutique investment firm whose entire reason for existing was to drive business and capital between the United States, Europe, Greater China, and the broader Asia region. This is one of the hardest lanes in biotech - different regulators, different investors, different expectations about how a deal gets done - and she spent ten-plus years living in it.
That experience travels with her. As a Venture Partner at BVCF (the Bioveda China Fund), she sits on the investment side of the same corridor she once worked from the advisory side. She has been Managing Director at Amato and Partners, a capital markets advisor. And she was elected to the Board of Directors of BayHelix, the tight-knit network of senior Chinese life sciences leaders that functions as something between an alumni association and a power grid for the industry.
Put it together and you get a rare profile: someone equally fluent in the operating language of a Western biotech and the relationship language of Asian capital. In an industry where a single cross-Pacific partnership can fund years of research, that fluency is the whole game.
Before the investing, before the cross-border advisory work, there was the operating apprenticeship. Nearing came up inside the companies that built modern biotech. At Amgen through the late 1990s, she worked as a senior product manager and marketing director inside the business development and special projects group - the room where a drug stops being a science project and starts being a product. Stints connected to Merck and IBM Healthcare followed, the latter as a business development executive at the dawn of the 2000s, when "healthcare" and "technology" were just beginning their long, complicated marriage.
That operating grounding is the thing investors and founders quietly value most. Nearing has sat on the side that has to actually ship and sell, not just fund. She knows what a milestone really costs and how a commercialization plan falls apart. When she later moved into venture and advisory roles, she brought the operator's skepticism with her - the instinct to ask not just "is this exciting?" but "who is going to build it, and with what?"
By 2020 she was carrying the Chief Business Officer title at three companies at once - MaveriX Oncology, Expression Therapeutics, and Ethismos Research - the model sometimes called a "fractional" CBO. The idea is simple and demanding: early-stage companies need senior business leadership but can't yet afford it full-time, so one veteran runs the playbook for several of them in parallel. It is a job that rewards exactly her toolkit - a deep network, a fast read on a deal, and the discipline to keep multiple stories straight.
At Expression Therapeutics she is described as Chief Business Officer and angel investor, bringing, in the company's words, "vast investor relations experience and networks, both in the U.S. and the Greater China region." She has also served as a business advisor to AsedaSciences. The pattern across all of it is consistent: she is the person early companies bring in when the science is real but the path to capital is not yet drawn.
The academic path explains a lot. Nearing earned a B.A. in Economics, with distinction, from the University of Michigan, then a Master of Science, with honors, from Harvard University. Economics first, science second - a sequence that mirrors how she works. She reads a biotech the way an economist reads a market and a scientist reads a result, holding both lenses at once. It is why she can sit comfortably between a chemist explaining a cleavable linker and an investor asking about the path to a return.
Beyond the operating and investing work, she gives time to governance and the field itself. She serves as an Independent Director at MaveriX Oncology and sits on the Board of Directors and Executive Committee of a Washington D.C. foundation (RVF). Board work is where the network compounds - and Nearing's career suggests she understands that the relationships are the asset, carefully built over decades, one deal and one boardroom at a time.
There is no loud personal brand here, no manifesto, no podcast tour. The evidence of Kimberly Nearing is in the structure of her career: operator, advisor, investor, director, on both sides of the Pacific. She is the connective tissue. And in a field where the best science can still die for lack of a believer with a checkbook, connective tissue is not a supporting role. It is the load-bearing one.